{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T03:00:30Z","timestamp":1762052430450,"version":"build-2065373602"},"reference-count":46,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Minimally invasive surgery may not be an appropriate surgical approach in intermediate- and high-risk endometrial carcinoma, even though adjuvant therapy is given. The objective of this study was to evaluate the results of open surgery including lymphadenectomy without adjuvant therapy in patients with uterine-confined intermediate- and high-risk endometrioid endometrial carcinoma. Two hundred fifty-six patients with uterine-confined endometrioid endometrial carcinoma were treated with open surgery, including pelvic with or without para-aortic lymphadenectomy. Of the 81 patients with uterine-confined intermediate- or high-risk disease, 77 were treated with systematic lymphadenectomy without adjuvant therapy. Seven patients developed recurrence, comprising 5.5% (3\/55) and 18.2% (4\/22) of the intermediate- and high-risk patients, respectively. The time to recurrence was 1\u201366 months. The sites of recurrence were the vaginal apex (n = 2), lung (n = 2), vaginal sidewall (n = 1), pelvic lymph nodes (n = 1), and para-aortic to supraclavicular nodes (n = 1). Of these, five patients were alive without disease after salvage treatment, but two understaged high-risk patients died of disease. The five-year disease-specific survival rates of intermediate- and high-risk patients were 100% and 90%, respectively. The present study indicated that patients with uterine-confined intermediate- and high-risk endometrioid endometrial carcinoma had excellent survival when treated with open surgery, including lymphadenectomy alone. The safety of omitting adjuvant therapy should be evaluated in prospective randomized trials comparing open surgery with minimally invasive surgery.<\/jats:p>","DOI":"10.3390\/curroncol29050298","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T22:26:40Z","timestamp":1652999200000},"page":"3728-3737","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Open Surgery including Lymphadenectomy without Adjuvant Therapy for Uterine-Confined Intermediate- and High-Risk Endometrioid Endometrial Carcinoma"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5136-3050","authenticated-orcid":false,"given":"Isao","family":"Otsuka","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuto","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Mitani","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Kanamoto","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1200\/JCO.2011.38.8645","article-title":"Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study","volume":"30","author":"Walker","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.2017.2068","article-title":"Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: A randomized clinical trial","volume":"317","author":"Janda","year":"2017","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(08)61766-3","article-title":"Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study","volume":"373","author":"Kitchener","year":"2009","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/jnci\/djn397","article-title":"Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial","volume":"100","author":"Basile","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/ijgc-2019-000838","article-title":"A comparison of disease recurrence between robotic versus laparotomy approach in patients with intermediate-risk endometrial cancer","volume":"30","author":"Song","year":"2020","journal-title":"Int. J. Gynecol Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ygyno.2020.12.003","article-title":"Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer","volume":"160","author":"Philp","year":"2021","journal-title":"Gynecol Oncol"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ygyno.2021.06.013","article-title":"Factors associated with an increased risk of recurrence in patients diagnosed with high-grade endometrial cancer undergoing minimally invasive surgery: A study of the society of gynecologic oncology of Canada (GOC) community of practice (CoP)","volume":"162","author":"Feigenberg","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.7150\/ijms.55026","article-title":"Survival rates of patients who undergo minimally invasive surgery for endometrial cancer with cervical involvement","volume":"18","author":"Kim","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2020.04.684","article-title":"Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data","volume":"158","author":"Dai","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"634857","DOI":"10.3389\/fonc.2021.634857","article-title":"Tumor Molecular Features Predict Endometrial Cancer Patients\u2019 Survival After Open or Minimally Invasive Surgeries","volume":"11","author":"Dai","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0140-6736(09)62002-X","article-title":"Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): A retrospective cohort analysis","volume":"375","author":"Todo","year":"2010","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/1097-0142(19900501)63:9<1843::AID-CNCR2820630931>3.0.CO;2-F","article-title":"Operative treatment in stage I endometrial carcinoma with deep myometrial invasion and\/or grade 3 tumor surgically limited to the corpus uteri. No recurrence with only primary surgery","volume":"63","author":"Chen","year":"1989","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/gyno.2002.6630","article-title":"Is there a survival benefit to adjuvant radiotherapy in high-risk surgical stage I endometrial cancer?","volume":"86","author":"Ayhan","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0090-8258(03)00087-8","article-title":"Stage IC adenocarcinoma of the endometrium: Survival comparisons of surgically staged patients with and without adjuvant radiotherapy","volume":"89","author":"Straughn","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/sj.bjc.6600468","article-title":"Lymphadenectomy and adjuvant therapy in endometrial carcinoma: Role of adjuvant chemotherapy","volume":"87","author":"Otsuka","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0002-9378(97)70601-X","article-title":"Stage I corpus cancer: Is teletherapy necessary?","volume":"176","author":"Orr","year":"1997","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1006\/gyno.2001.6276","article-title":"Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy","volume":"82","author":"Fanning","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10147-016-0981-1","article-title":"Japan Society of Gynecologic Oncology guidelines 2013 for the treatment of uterine body neoplasms","volume":"21","author":"Ebina","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0090-8258(91)90086-K","article-title":"Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group Study","volume":"40","author":"Morrow","year":"1991","journal-title":"Gynecol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.2015.65.3212","article-title":"Comparative Effectiveness of Minimally Invasive Hysterectomy for Endometrial Cancer","volume":"34","author":"Wright","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2014.01.041","article-title":"The impact of obesity on surgical staging, complications, and survival with uterine cancer: A Gynecologic Oncology Group LAP2 ancillary data study","volume":"133","author":"Gunderson","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/bjc.2011.46","article-title":"High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer","volume":"104","author":"Mauland","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"592.e1\u201311","DOI":"10.1016\/j.ajog.2017.01.027","article-title":"The effect of a uterine manipulator on the recurrence and mortality of endometrial cancer: A multi-centric study by the Italian Society of Gynecological Endoscopy","volume":"216","author":"Uccella","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"65.e1","DOI":"10.1016\/j.ajog.2020.07.025","article-title":"Impact of uterine manipulator on oncological outcome in endometrial cancer surgery","volume":"224","author":"Lago","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/cncr.22185","article-title":"Therapeutic role of lymph node resection in endometrioid corpus cancer. A study of 12,333 patients","volume":"107","author":"Chan","year":"2006","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"457.e1","DOI":"10.1016\/j.ajog.2008.01.010","article-title":"Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?","volume":"198","author":"Iasonos","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1470-2045(07)70275-9","article-title":"Role of complete lymphadenectomy in endometrioid uterine cancer","volume":"8","author":"Chan","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ejso.2013.01.002","article-title":"Impact of lymphadenectomy in uterine endometrioid carcinoma","volume":"39","author":"Huang","year":"2013","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100869","DOI":"10.1016\/j.gore.2021.100869","article-title":"Long-term survival of a patient with stage IIIC2 grade 3 endometrioid endometrial carcinoma treated with surgery alone","volume":"38","author":"Otsuka","year":"2021","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1470-2045(11)70070-5","article-title":"Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: A prospective multicentre study (SENTI-ENDO)","volume":"12","author":"Ballester","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1470-2045(17)30068-2","article-title":"A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): A multicentre, prospective, cohort study","volume":"18","author":"Rossi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ygyno.2018.08.022","article-title":"Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy","volume":"151","author":"Schlappe","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ygyno.2014.09.011","article-title":"Sentinel node biopsy for the management of early stage endometrial cancer: Long-term results of the SENTI-ENDO study","volume":"136","author":"Dubernard","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ygyno.2010.08.013","article-title":"Predictive factors for prolonged survival in recurrent endometrial carcinoma: Implications for follow-up protocol","volume":"119","author":"Otsuka","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre random trial","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study","volume":"24","author":"Randall","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2007.09.029","article-title":"Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study","volume":"108","author":"Susumu","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ygyno.2008.10.019","article-title":"Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence","volume":"112","author":"Fujimoto","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ygyno.2014.01.007","article-title":"Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: A histologic dichotomy","volume":"132","author":"Mariani","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_41","first-page":"825","article-title":"Surgical staging in endometrial cancer: Clinical-pathologic findings of a prospective study","volume":"63","author":"Boronow","year":"1984","journal-title":"Obstet. Gynecol."},{"doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67\u201373.","key":"ref_42","DOI":"10.1038\/nature12113"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2017.10.037","article-title":"An NRG Oncology\/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer","volume":"148","author":"Cosgrove","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cncr.31901","article-title":"Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker","volume":"125","author":"Backes","year":"2019","journal-title":"Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"90.e1","DOI":"10.1016\/j.ajog.2021.08.011","article-title":"Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: A prospective cohort study","volume":"226","author":"Forsse","year":"2022","journal-title":"Am. J. Obstet. Gynecol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/5\/298\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:15:06Z","timestamp":1760138106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/5\/298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["curroncol29050298"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29050298","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2022,5,19]]}}}